Browse resources

Disease: Pneumococcus

Total results with these characteristics: 196

Page 6 of 8  
‹ prev.
3
4
5
6
7
8
next ›

Potential Impact of Accelerating the Primary Dose of Pneumococcal Conjugate Vaccine in Infants

This article, published in Archives of Pediatrics and Adolescent Medicine, estimates the potential effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from two months to six weeks of age. The …

Author: Stancil JM, Peters TR, Givner LB, Poehling KA

Published: 2009

Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases

Children younger than two years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80 percent of invasive disease …

Author: O'Brien K, Santosham M

Published: 2004

The Potential Indirect Effect of Conjugate Pneumococcal Vaccines

Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive …

Author: O'Brien K, Dagan R

Published: 2003

Preformulation Characterization of an Aluminum Salt-Adjuvanted Trivalent Recombinant Protein-Based Vaccine Candidate Against Streptococcus pneumoniae

This article, published in the Journal of Pharmaceutical Sciences, describes a study where candidate formulations of a trivalent recombinant protein vaccine containing aluminum hydroxide adjuvant for protection against S. pneumoniae were identified …

Author: Iyer V, Hu L, Liyanage MR, et al.

Published: 2012

Prevenar Experience

This article, published in Vaccine, reviews the history of pneumococcal vaccines with a focus on the first heptavalent conjugated pneumococcal vaccine (PCV7), which was first licensed in the United States in 2000, followed by many other countries. …

Author: Arguedas A, Soley C, Abdelnour A

Published: 2011

Prevenar™ Vaccination: Review of the Global Data, 2006

This article, published in the journal Vaccine, reviews the incidence of vaccine-serotype invasive pneumococcal disease and other pneumococcal-associated respiratory tract diseases following the routine use of the seven-valent pneumococcal conjugate …

Author: Center KJ

Published: 2007

The Preventable Burden of Pneumococcal Disease in the Developing World

The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. …

Author: Scott JA

Published: 2007

Preventing Pneumococcal Disease Among Infants and Young Children

This report includes the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices recommended pneumococcal vaccination schedule for infants at ages 2, 4, 6, and 12 to 15 months. This report also includes a …

Author: US Centers for Disease Control and Prevention

Published: 2000

Prevention and Control of Childhood Pneumonia

This special edition of the Bulletin of the World Health Organization focuses on the prevention and control of childhood pneumonia. It highlights research on the many aspects that drive this deadly disease and the progress now …

Author: World Health Organization

Published: 2008

Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine

This report, published by the US Centers for Disease Control and Prevention (CDC), summarizes recommendations approved by the CDC's Advisory Committee on Immunization Practices (ACIP) on February 24, 2010, for the use of 13-valent …

Author: US Centers for Disease Control and Prevention

Published: 2010

Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Published in the CDC's Morbidity and Mortality Weekly Report, this article provides recommendations on the use of pneumococcal polysaccharide vaccines to prevent pneumococcal disease.

Author: US Centers for Disease Control and Prevention

Published: 1997

Prevention of Pneumococcal Disease Through Vaccination

This article, published in Vaccine, reviews background information on the diagnosis and treatment of pneumonia and pneumococcal disease in children, as well as the history and benefits of vaccination against pneumococcal disease. The authors …

Author: Gentile A, Bazán V

Published: 2011

Prevnar13®, Pneumococcal 13-valent Conjugate Vaccine

This website provides information on Pfizer's (formerly Wyeth's) 13-valent pneumococcal conjugate vaccine, including usage and safety information.

Author: Wyeth Pharmaceuticals and Pfizer Inc.

Procurement and Pricing of New Vaccines for Developing Countries

Several vaccines that have come to market, including the rotavirus, pneumococcal conjugate, and human papillomavirus vaccines, have the potential to bring large public health benefits to developing countries. This eight-page policy brief explains …

Author: International AIDS Vaccine Initiative

Published: 2008

Projected Cost-Effectiveness of Pneumococcal Conjugate Vaccination of Healthy Infants and Young Children

This study, published in the Journal of American Medical Association, evaluates the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children through a cost-effectiveness analysis based …

Author: Lieu TA, Ray GT, Black SB, et al.

Published: 2000

Projected Health Benefits and Costs of Pneumococcal and Rotavirus Vaccination in Uganda

The authors of this article, published in Vaccine, determined the impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children younge than five years of age in Uganda from the public health system perspective. They …

Author: Tate JE, Kisakye A, Mugyenyi P, Kizza D, Odiit A, Braka F

Published: 2011

The Promise of Conjugate Vaccines for Africa

This article, published in Vaccine, emphasizes the importance of capsular polysaccharide vaccines for preventing disease caused by Neisseria meningitidis and Streptococcus pneumoniae in Africa, reiterating that these vaccines have been proven safe …

Author: Kieny MP, LaForce FM

Published: 2007

Prospective Multicentre Hospital Surveillance of Streptococcus Pneumoniae Disease in India

The Network studied the characteristics of invasive pneumococcal infections in six hospitals in India over four years, in patients with suspected pneumonia (3686), pyogenic meningitis (1107), septicaemia (257), or localised …

Author: Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN)

Published: 1999

Protecting Aluminum-Adjuvanted Vaccines From Freeze Damage

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global …

Author: PATH

Published: 2012

Protecting Child Health for a Promising Future

This fact sheet provides a snapshot of PATH's programs that tackle the leading causes of childhood illness and death: pneumonia, diarrheal disease, and malaria. It profiles PATH's work on new and innovative vaccines, medicines, diagnostics, and …

Author: PATH

Published: 2012

Protecting the Herd: The Remarkable Effectiveness of the Bacterial Meningitis Polysaccharide-Protein Conjugate Vaccines in Altering Transmission Dynamics

The polysaccharide-protein conjugate vaccines against the pathogens responsible for bacterial meningitis have demonstrated remarkable effectiveness, far beyond the predicted individual efficacy. Approximately half of the effectiveness of these …

Author: Stephens DS

Published: 2011

Protein Carriers of Conjugate Vaccines: Characteristics, Development and Clinical trials

This article, published in Human Vaccines & Immunotherapeutics, discusses the conjugate vaccines for preventing infections caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis. It specifically …

Author: Pichichero ME

Published: 2013

ProVac Pneumococcal e-Learning Course

This online course is a practical tool designed to aid policy makers, national-level managers of immunization programs and other experts in making evidence-based decisions regarding the introduction of conjugate pneumococcal vaccines into national …

Author: Pan American Health Organization

PubMed Searches: Pneumococcal Disease

These pre-formatted PubMed searches will retrieve journal citations and available abstracts that address disease burden, vaccine efficacy and benefits, model programs and cost issues in Asian, African, and Latin American countries.  Documents …

Author: Various

Rapid Pneumococcal Evolution in Response to Clinical Interventions

This article, published in Science, describes a study detailing how genomic plasticity within lineages of recombinogenic bacteria can permit adaptation to clinical interventions over remarkably short time scales. ABSTRACT ONLY: (Learn how …

Author: Croucher NJ, Harris SR, Fraser C, et al.

Published: 2011

Page 6 of 8  
‹ prev.
3
4
5
6
7
8
next ›